Silver Book Fact

“A treatment breakthrough that delayed the age of onset of Alzheimer’s disease by five years and began to show its effects in 2015 would decrease the total number of Americans age 65 and older with Alzheimer’s disease from 5.6 million to 4 million by 2020.  As a result, 1.6 million Americans who would be expected to have the condition in 2020 would be free of the condition.  In addition, five years later, in 2025, 2.7 million Americans–42 percent of the 6.5 million people who would be expected to have Alzheimer’s in that year–would be disease free.  The biggest effect would be in 2050 when 5.8 million people–43 percent of the 13.5 million Americans who would be expected to have Alzheimer’s without the breakthrough–would not have the condition.”

Alzheimer's Association. Changing the Trajectory of Alzheimer’s Disease: How a treatment by 2025 saves lives and dollars. Washington, D.C.: Alzheimer’s Association; 2010. http://www.alz.org/documents_custom/trajectory.pdf

Reference

Title
Changing the Trajectory of Alzheimer’s Disease: How a treatment by 2025 saves lives and dollars
Publisher
Alzheimer’s Association
Publication Date
2010
Authors
Alzheimer's Association
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Human Value

Related Facts

  • A recent study showed that memantine, a medicine approved to treat moderate-to-severe Alzheimer’s, significantly slows cognitive decline and reduces the need for caregiving by 45.8 hours per month.  
  • Impact of a 5-Year Delay in Onset on Costs, Americans Age 65 and Older with Alzhemier’s Disease, 2010-2050  
  • Donepezil, a cholinesterase inhibitor, has been found to slow progression of Alzheimer’s disease in its early stages, delaying the need for nursing home care by an average of 30 months.  
  • A $1 billion-investment in Alzheimer’s research that led to research breakthroughs by 2010 could have a 10-to-1 return by 2015, and a 90-to-1 return by 2050.  
  • Impact of Slowed Progression by Stage of Disease, Americans Age 65 and Older with Alzheimer’s Disease, 2050